Ozempic and Wegovy, the blockbuster but costly GLP-1 drugs often used for weight loss, are among the 15 medications that will ...

U.S. Health and Human Services Secretary Xavier Becerra says “this is a big deal.” Drug companies oppose the program.

Federal officials are targeting the blockbuster drugs as part of their ongoing initiative to lower drug costs.

Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss treatment Wegovy are among the 15 drugs targeted for ...

A range of GLP-1 weight loss drugs are currently on the market. What are they, what do they do, and where are they available?

As the weight-loss drugs become more popular, consumer habits are starting to reflect changing consumption behavior, ...

Many viewers of the 2025 Golden Globes quickly noticed stars who seemed to have embraced GLP-1 medications that help people ...

Novo Nordisk has claimed an edge in the increasingly competitive obesity therapy category after ... label for Wegovy to include a cardiovascular outcomes claim in the US and Europe before the ...

Monday, Dec. 2, 2024. (AP Photo/Kathleen Batten) Patient Lory Osborn holds a Wegovy pen used in her treatment at the Medical Weight Management office at West Virginia University in Morgantown, W.Va., ...

According to the study, participants taking Zepbound lost an average of 20.2% of their starting weight after 72 weeks, compared to a 13.7% loss for those on Wegovy, which Lilly billed as proof ...

Zepbound’s superior efficacy and strategic market expansion suggest that the drug will dominate the obesity market, surpassing Novo Nordisk’s Wegovy (semaglutide), according to GlobalData ...